| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3865214 | The Journal of Urology | 2013 | 6 Pages |
Abstract
Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles.
Keywords
GnRHPSAHDLSERMVTEBMDADThigh-density lipoproteinProstate specific antigenBone mineral densityToremifeneADT, Androgen deprivation therapyVenous thromboembolic eventadverse eventLow-density lipoproteinLDLSelective estrogen receptor modulatorsSelective estrogen receptor modulatorProstatic neoplasmsGonadotropin-releasing hormoneOsteoporosis
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Matthew R. Smith, Ronald A. Morton, K. Gary Barnette, Paul R. Sieber, S. Bruce Malkowicz, Domingo Rodriguez, Michael L. Hancock, Mitchell S. Steiner,